Managing Type 2 Diabetes From Diagnosis Through Disease Progression: Role of GLP-1 Receptor Agonists in Therapy
Case Study 1: Managing Recent-Onset Diabetes: Choosing Well-Tolerated Therapies With Durability to Add to Metformin or in Metformin-Intolerant Patients
Jay H. Shubrook, Jr., DO, FACOFP, FAAFP
Director, Diabetes Endocrine Center
Director, Diabetes Fellowship
The Diabetes Institute at Ohio University, Athens, Ohio
Case Study 2: What to Do When There is a Loss of Glycemic Control: Insulin or Incretins?
Thomas B. Repas, DO, FACP, FACE, FACOI, FNLA, CDE
Clinical Assistant Professor
Department of Medicine
Sanford School of Medicine
University of South Dakota
Rapid City, South Dakota
Case Study 3: Managing Diabetes in Patients With Disease of Long Duration: GLP-1 Receptor Agonists and Insulin in Combination
Etie S. Moghissi, MD, FACP, FACE
Associate Clinical Professor
Department of Medicine
University of California – Los Angeles
Los Angeles, California
About This Activity
This enduring activity was developed in part from a CE-certified symposium held on Thursday, October 3, 2013, during OMED 2013 Osteopathic Medical Conference & Exposition in Las Vegas, Nevada.
This CE activity is intended for osteopathic physicians and other healthcare professionals involved in the care of patients with type 2 diabetes.
After completing this activity learners should be better able to:
Identify different concerns and pathophysiologic considerations that exist for patients at different times in the course of diabetes progression
Differentiate GLP-1 receptor agonists from traditional glucose-lowering agents with respect to A1C lowering effects, weight effects, and risks of hypoglycemia
Explain the differences between GLP-1 receptor agonist therapy and DPP-4 inhibitor therapy in patient-centered language
Describe how GLP-1 receptor agonists may be used as monotherapy, part of combination therapy strategies, with insulin, and over the course of diabetes
Credit Designation Statement
The American Osteopathic Association designates this activity for a maximum of 1.50 hours of Category- 1B credit.
Planning Committee Disclosures
Laurie Ermentrout states that she has no relevant financial relationship to disclose.
Kate Mann, PharmD, states that she has no relevant financial relationship to disclose.
This enduring activity is supported by an educational grant from Novo Nordisk Inc.